<DOC>
	<DOC>NCT01244165</DOC>
	<brief_summary>To evaluate safety and effectiveness of using the fetal bovine dermis (Cytrix) in the treatment of pelvic organ prolapse.</brief_summary>
	<brief_title>Study of Cytrix Use in Pelvic Floor Prolapse Treatment</brief_title>
	<detailed_description />
	<mesh_term>Prolapse</mesh_term>
	<mesh_term>Pelvic Organ Prolapse</mesh_term>
	<criteria>Female &gt;30 years of age Willing and able to comply w/ the study procedures and provide written informed consent to participate in the study. Diagnosed with pelvic organ prolapse with or without pelvis floor dysfunction Patient is willing to complete PFDISF20 and PISQ12 questionnaires at 6 and 12 months postoperatively Patient is willing to answer phone questionnaires at 2 weeks, 6 weeks, and 3 months Patients with a history of pelvic surgery (cystocele/anterior repair, hysterectomy, vault suspension, etc) prior to this procedure are allowed to participate in the study except if the patient had a dermal graft implanted. Patients who, in the clinical judgment of the investigator, are not suitable for this study Patients who are, in the Investigators opinion, mentally or legally incapacitated preventing informed consent or unable to read or understand written material. Patients who have participated in an investigational study within 30 days of study entry that may impact analysis of this device or have previously participated in the current trial Patient whose pelvic organ prolapse is Stage I Patient with Diabetes Mellitus type I or II Patient with morbid obesity (weight parameters determined by physician) Patient with undiagnosed pelvic mass outside of the uterus (not expected to be functional in nature) Patient with unexplained abnormal menstrual bleeding Patient with any acute or chronic infection (kidney, bladder, lung, etc) Patient with coagulopathy Patient participating in other investigational device or drug study Patients must not be pregnant Patients with life expectancy less than 2 years Patients with known or suspected hypersensitivity to collagen or bovine products Patients with preexisting local or systemic infection Patients with a history of soft tissue pathology where the implant is to be placed Patients with any pathology that would limit the blood supply and compromise healing Patient diagnosed with autoimmune connective tissue disease</criteria>
	<gender>Female</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>November 2010</verification_date>
</DOC>